July 24, 2025
2 min watch
SALT LAKE CITY — On this Healio Video Perspective from the ARVO assembly, Michael Javaheri, MD, overviews real-world knowledge on Eylea HD in diabetic macular edema and moist age-related macular degeneration.
Javaheri reported a median remedy interval of 70 days in treatment-naive sufferers with DME or moist AMD.
Moreover, sufferers with preliminary remedy intervals of lower than 6 weeks skilled remedy extensions of two to three weeks after switching to Eylea HD (aflibercept injection 8 mg, Regeneron) from different anti-VEGF brokers. Sufferers with preliminary remedy intervals that have been longer than 6 weeks skilled extensions of three to 4 weeks.
“This bodes very effectively for our sufferers in permitting them to get nice visible positive aspects and to be prolonged to bigger intervals, as we might have thought with the usage of Eylea HD,” Javaheri stated.
References:
- Ali FS, et al. Early real-world use of aflibercept 8 mg in treatment-naive sufferers with neovascular age-related macular degeneration. Introduced at: Affiliation for Analysis in Imaginative and prescient and Ophthalmology assembly; Could 4-8, 2025; Salt Lake Metropolis.
- Javaheri M, et al. Early insights from real-world use of aflibercept 8 mg amongst eyes with diabetic macular edema (DME) switching from different anti-VEGF brokers. Introduced at: Affiliation for Analysis in Imaginative and prescient and Ophthalmology assembly; Could 4-8, 2025; Salt Lake Metropolis.
- Leng T, et al. Early insights from real-world use of aflibercept 8 mg amongst eyes with neovascular age-related macular degeneration (nAMD) switching from different anti-VEGF brokers. Introduced at: Affiliation for Analysis in Imaginative and prescient and Ophthalmology assembly; Could 4-8, 2025; Salt Lake Metropolis.
- Mehta N, et al. Early insights on the real-world use of aflibercept 8 mg amongst treatment-naive eyes with diabetic macular edema. Introduced at: Affiliation for Analysis in Imaginative and prescient and Ophthalmology assembly; Could 4-8, 2025; Salt Lake Metropolis.
Sources/Disclosures
Collapse
Healio interviews
Disclosures:
Javaheri experiences being a speaker, marketing consultant and researcher for Apellis Prescribed drugs and a speaker and marketing consultant for Regeneron.
